Eribulin

Generic Name
Eribulin
Brand Names
Halaven, Eribulin Baxter, Mevlyq
Drug Type
Small Molecule
Chemical Formula
C40H59NO11
CAS Number
253128-41-5
Unique Ingredient Identifier
LR24G6354G
Background

Eribulin is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Eribulin was isolated from the marine sponge Halichondria okadai. Eribulin is also being investigated for use in the treatment of advanced solid ...

Indication

For the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic cancer.

Associated Conditions
Metastatic Liposarcoma, Refractory, metastatic Breast cancer, Unresectable Liposarcoma
Associated Therapies
-
Clinical Trials
Related News

Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer

First Posted Date
2020-10-08
Last Posted Date
2024-12-17
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
184
Registration Number
NCT04579224
Locations
🇺🇸

Cancer Hematology Centers - Flint, Flint, Michigan, United States

🇺🇸

Kingman Regional Medical Center, Kingman, Arizona, United States

🇺🇸

Cancer Center at Saint Joseph's, Phoenix, Arizona, United States

and more 410 locations

Maintenance Treatment With Eribulin Mesylate Versus Observation in Triple Negative Breast Cancer Patients

First Posted Date
2020-08-06
Last Posted Date
2020-08-11
Lead Sponsor
The First Affiliated Hospital with Nanjing Medical University
Target Recruit Count
100
Registration Number
NCT04502680
Locations
🇨🇳

Jiangsu Provincial Hospital, Nanjing, Jiangsu, China

Ipatasertib Plus Non-Taxane Chemotherapy for Advanced or Metastatic Triple-Negative Breast Cancer

First Posted Date
2020-07-09
Last Posted Date
2024-07-26
Lead Sponsor
MedSIR
Target Recruit Count
54
Registration Number
NCT04464174
Locations
🇪🇸

Hospital Quiron San Camilo- Ruber Juan Bravo, Madrid, Spain

🇪🇸

Hospital Universitario Ramón y Cajal, Madrid, Spain

🇵🇹

Champalimaud Clinical Centre - Champalimaud Foundation, Lisboa, Portugal

and more 11 locations

Testing the Addition of Copanlisib to Eribulin for the Treatment of Advanced-Stage Triple Negative Breast Cancer

First Posted Date
2020-04-15
Last Posted Date
2024-12-18
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
106
Registration Number
NCT04345913
Locations
🇺🇸

Smilow Cancer Hospital Care Center at Long Ridge, Stamford, Connecticut, United States

🇺🇸

Memorial Hospital East, Shiloh, Illinois, United States

🇺🇸

University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida, United States

and more 40 locations

A Phase II Trial of Camrelizumab in Combination With Apatinib and Eribulin in Patients With Advanced TNBC

Phase 2
Active, not recruiting
Conditions
Breast Cancer
Interventions
Drug: Camrelizumab
Drug: Apatinib
Drug: Eribulin
First Posted Date
2020-03-11
Last Posted Date
2023-04-12
Lead Sponsor
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Target Recruit Count
46
Registration Number
NCT04303741
Locations
🇨🇳

The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China

🇨🇳

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China

🇨🇳

Changhai Hospital, Navy Medical University (Second Military Medical University), Shanghai, Shanghai, China

Breast Cancer Treatment Based on Organ-like Culture

First Posted Date
2019-04-24
Last Posted Date
2019-04-24
Lead Sponsor
Xijing Hospital
Target Recruit Count
300
Registration Number
NCT03925233
Locations
🇨🇳

JingSu, Xi'an, Shaanxi, China

Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Participants With HR+/HER2- Metastatic Breast Cancer

First Posted Date
2019-04-03
Last Posted Date
2024-10-21
Lead Sponsor
Gilead Sciences
Target Recruit Count
543
Registration Number
NCT03901339
Locations
🇺🇸

The University of Kansas Cancer Center, Westwood, Kansas, United States

🇺🇸

University of Chicago Medical Center, Chicago, Illinois, United States

🇺🇸

Maryland Oncology Hematology, P.A., Rockville, Maryland, United States

and more 110 locations

A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue Sarcomas

First Posted Date
2019-04-02
Last Posted Date
2024-12-03
Lead Sponsor
Dana-Farber Cancer Institute
Target Recruit Count
57
Registration Number
NCT03899805
Locations
🇺🇸

Dana Farber Cancer Institute, Boston, Massachusetts, United States

🇺🇸

Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States

Eribulin in Advanced Solitary Fibrous Tumor

Phase 2
Recruiting
Conditions
Solitary Fibrous Tumor
Interventions
Drug: Eribulin
First Posted Date
2019-02-15
Last Posted Date
2023-09-13
Lead Sponsor
Italian Sarcoma Group
Target Recruit Count
16
Registration Number
NCT03840772
Locations
🇮🇹

Azienda Ospedaliera Universitaria Paolo Giaccone, Palermo, PA, Italy

🇮🇹

Policlinico Universitario Campus Biomedico, Roma, RM, Italy

🇮🇹

Fondazione IRCCS INT Milano, Milano, Italy

Trial With Eribulin or Eribulin+ Endocrine Therapy in Locally-recurrent or Metastatic Breast Cancer Patients

Phase 2
Terminated
Conditions
Breast Cancer
Interventions
Drug: Eribulin
First Posted Date
2019-01-07
Last Posted Date
2021-08-31
Lead Sponsor
MedSIR
Target Recruit Count
22
Registration Number
NCT03795012
Locations
🇪🇸

Hospital Son Llatzer, Palma De Mallorca, Spain

🇪🇸

Complejo Asistencial Universitario de León, León, Spain

🇪🇸

Hospital Universitario Dr Peset, Valencia, Spain

and more 6 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy